Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Price

APLSStock

$0.00−2.20%52W

Market Cap—

P/E234.62x

PEG Ratio—

Div yield—

Beta-0.20

APLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)96.11%

Price vs S&P 500 (4W)-5.40%

VGM Score63.29

P/E Ratio (Annual)234.62x

P/CF (Annual)115.88x

Book Value / Share (Quarterly)$3.24

P/TBV (Annual)33.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)137.00%

Cash Flow / Share (Quarterly)$0.29

Price vs S&P 500 (YTD)54.48%

Gross Margin (TTM)90.19%

Net Profit Margin (TTM)12.06%

EPS (TTM)$1.00

10-Day Avg Trading Volume11.48M

EPS Excl Extra (TTM)$1.00

Revenue Growth (5Y)31.99%

EPS (Annual)$0.18

ROI (Annual)2.71%

Gross Margin (Annual)89.81%

Net Profit Margin (5Y Avg)-428.42%

Cash / Share (Quarterly)$3.17

P/E Basic Excl Extra (TTM)39.41x

Revenue Growth QoQ (YoY)60.85%

P/E Normalized (Annual)234.62x

ROA (Last FY)2.08%

Revenue Growth TTM (YoY)42.46%

EBITD / Share (TTM)$1.30

ROE (5Y Avg)-222.36%

Operating Margin (TTM)14.95%

Cash Flow / Share (Annual)$0.36

P/B Ratio12.66x

P/B Ratio (Quarterly)12.40x

Net Income / Employee (Annual)$30,500

EV / Revenue (TTM)4.80x

Net Interest Coverage (TTM)1.77x

ROA (TTM)13.20%

EV / EBITDA (TTM)31.83x

EPS Incl Extra (Annual)$0.18

Current Ratio (Annual)3.14x

Quick Ratio (Quarterly)3.01x

3-Month Avg Trading Volume5.45M

52-Week Price Return-2.20%

EV / Free Cash Flow (Annual)117.82x

P/E Incl Extra (TTM)39.41x

Revenue / Employee (TTM)$1,507,900

Tangible BV / Share (Quarterly)$1.96

P/S Ratio (Annual)5.23x

Asset Turnover (Annual)0.93x

52-Week High$41.14

Operating Margin (5Y Avg)-386.90%

EPS Excl Extra (Annual)$0.18

CapEx CAGR (5Y)-43.47%

Tangible BV CAGR (5Y)2.66%

26-Week Price Return105.66%

Quick Ratio (Annual)2.59x

13-Week Price Return81.71%

Total Debt / Equity (Annual)1.23x

Current Ratio (Quarterly)3.63x

Enterprise Value$5.30B

Revenue / Share Growth (5Y)19.02%

Asset Turnover (TTM)1.09x

Book Value / Share Growth (5Y)1.69%

Revenue / Employee (Annual)$1,369,400

Inventory Turnover (Annual)0.91x

Pretax Margin (Annual)2.40%

Cash / Share (Annual)$3.68

3-Month Return Std Dev268.65%

Gross Margin (5Y Avg)88.95%

Net Income / Employee (TTM)$181,800

ROE (Last FY)6.05%

Net Interest Coverage (Annual)5.48x

EPS Basic Excl Extra (Annual)$0.18

P/FCF (TTM)39.78x

Receivables Turnover (TTM)3.27x

EV / Free Cash Flow (TTM)141.55x

Total Debt / Equity (Quarterly)1.10x

EPS Incl Extra (TTM)$1.00

Receivables Turnover (Annual)3.18x

ROI (TTM)16.86%

P/S Ratio (TTM)4.75x

Pretax Margin (5Y Avg)-427.94%

Revenue / Share (Annual)$7.96

Tangible BV / Share (Annual)$1.53

Price vs S&P 500 (52W)-13.62%

P/E Ratio (TTM)39.41x

Year-to-Date Return63.34%

5-Day Price Return0.05%

EPS Normalized (Annual)$0.18

ROA (5Y Avg)-51.55%

Net Profit Margin (Annual)2.23%

Month-to-Date Return0.20%

Cash Flow / Share (TTM)$-5.21

EBITD / Share (Annual)$0.45

Operating Margin (Annual)5.52%

LT Debt / Equity (Annual)0.98x

P/CF (TTM)139.07x

ROI (5Y Avg)-64.42%

P/E Excl Extra (TTM)39.41x

LT Debt / Equity (Quarterly)0.87x

EPS Basic Excl Extra (TTM)$1.00

P/TBV (Quarterly)24.69x

P/B Ratio (Annual)8.59x

Inventory Turnover (TTM)1.01x

Pretax Margin (TTM)12.23%

Book Value / Share (Annual)$2.92

Price vs S&P 500 (13W)74.46%

Beta-0.20x

P/FCF (Annual)116.69x

Revenue / Share (TTM)$8.41

ROE (TTM)39.71%

52-Week Low$16.83

vGradeD

gGradeB

mGradeA

vgmGradeB

APLS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.41

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
APLSApellis Pharmaceuticals, Inc. Common Stock	D	B	A	4.8x	42.5%	90.2%	—	$0.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Apellis Pharmaceuticals, Inc. Common Stock

Apellis Pharmaceuticals commercializes complement system inhibitors for diseases with significant unmet treatment needs. The company markets two C3-targeted therapies, SYFOVRE and EMPAVELI (both pegcetacoplan-based), which inhibit a central immune pathway and represent meaningful commercial opportunities in complement-driven immune diseases.